This is a dilutive capital raise for a cash-strapped clinical-stage biotech with a going-concern warning. The massive warrant overhang (2.9M ADSs from pre-funded and private placement warrants vs. ~4.4M ADSs currently outstanding) will pressure the stock. Monitor for potential near-term selling as the investor may hedge its position. The 60-day lock-up on the company and insiders provides a temporary floor, but the overhang is significant.
Price Chart
Executive Summary
BioLineRx is raising approximately $3.3 million in net proceeds through a registered direct offering of 480,696 ADSs and pre-funded warrants to purchase 868,225 ADSs, alongside a concurrent private placement of warrants to purchase 2,023,382 ADSs, all priced at $2.78 per ADS. The offering is highly dilutive, increasing the share count by ~11% from ADSs alone, with massive additional overhang from the pre-funded and private placement warrants representing up to 1.7 billion ordinary shares. The company's auditors included a going-concern explanatory paragraph in the most recent annual report, underscoring the necessity of this capital raise for a clinical-stage biotech with an $11M market cap.
Key Facts
- Gross proceeds of $3.75 million from the offering of 480,696 ADSs and pre-funded warrants for 868,225 ADSs.
- Net proceeds to the company are estimated at approximately $3.3 million after fees and expenses.
- A concurrent private placement adds warrants to purchase 2,023,382 ADSs (1.2 billion ordinary shares) at $2.78 per ADS, exercisable for five years.
- Existing warrants held by the same investor for 277,273 ADSs were repriced to $2.78 and extended to August 31, 2031.
- The offering price of $2.78 was at a slight premium to the August 27, 2026 closing price of $2.76.
- Immediate dilution of $1.16 per ADS for new investors, based on a pro forma as-adjusted net tangible book value of $1.62 per ADS.
- The company's auditors included a going-concern explanatory paragraph in the financial statements for the year ended December 31, 2025.
- The company is a clinical-stage biopharmaceutical firm with an $11M market cap, focused on GLIX1 and motixafortide.
- The offering includes a 60-day lock-up for the company and its directors/officers, and a 120-day ban on variable-rate transactions.
- A tail financing fee of $262,500 cash and warrants for 67,446 ADSs at $3.475 per ADS is owed to prior placement agent H.C. Wainwright.
Financial Impact
Net proceeds of ~$3.3 million raised, with immediate dilution of $1.16 per ADS for new investors. The concurrent private placement adds massive potential dilution from warrants for 2,023,382 ADSs.
Risk Factors
- Massive dilution from the offering and concurrent private placement warrants, representing up to 1.7 billion ordinary shares.
- Going-concern risk highlighted by auditors in the most recent annual report.
- Clinical-stage pipeline with no near-term revenue catalysts; reliance on partnerships for motixafortide and early-stage GLIX1 program.
- Geopolitical risk due to operations in Israel amid ongoing regional conflicts.
- Nasdaq delisting risk if new MVLS rule is implemented and market cap falls below $5 million.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 424B5 Filing (Primary) | 0001178913-26-004339 |
| Document: 0001178913-26-004339-index-headers.html | 0001178913-26-004339 |
| Document: 0001178913-26-004339-index.html | 0001178913-26-004339 |
| Document: 0001178913-26-004339.txt | 0001178913-26-004339 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 23, 2026 3d ago | 6-K | $2.04 | awaiting T+20 | — | $2.01 (−1.47%) |
Oct 5, 2026 21d ago | EFFECT | $2.32 | awaiting T+20 | — | $2.01 (+13.36%) |
Sep 25, 2026 4w ago | F-1 | $2.43 $2.00 | ▼ −17.70% | ▼ −17.66% | $2.01 (−17.28%) |
Sep 10, 2026 6w ago | 6-K | $2.57 $2.21 | ▼ −13.99% | ▼ −16.12% | $2.01 (−21.77%) |
Aug 31, 2026 8w ago | 424B5 | $2.80 $2.36 | ▲ +15.71% | ▲ +15.34% | $2.01 (+28.21%) |
Aug 31, 2026 8w ago | 6-K | $2.80 $2.36 | ▲ +15.71% | ▲ +15.34% | $2.01 (+28.21%) |
Aug 31, 2026 8w ago | 6-K | $2.80 $2.36 | ▲ +15.71% | ▲ +15.34% | $2.01 (+28.21%) |
Aug 28, 2026 8w ago | 6-K | $2.60 $2.43 | ▲ +6.54% | ▲ +6.80% | $2.01 (+22.69%) |
Aug 28, 2026 8w ago | Press Release | $2.60 $2.43 | ▲ +6.54% | ▲ +6.80% | $2.01 (+22.69%) |
Jul 8, 2026 15w ago | 6-K | $3.01 $2.72 | ▼ −9.73% | ▼ −13.01% | $2.01 (−33.22%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers